Merck Stock Soars 50% in 6 Months: Buy, Hold, or Take Profits?

MRK shares have surged over 50% in the past six months, but looming patent risks and weak vaccine sales raise questions about sustainability. Patent/IP exposure and underperforming vaccine revenue increase downside risk and argue for reassessing positions or trimming gains given potential valuation pressure.

Analysis

MRK shares have surged over 50% in the past six months, but looming patent risks and weak vaccine sales raise questions about sustainability. Patent/IP exposure and underperforming vaccine revenue increase downside risk and argue for reassessing positions or trimming gains given potential valuation pressure.